What is the most common age for nasopharyngeal carcinoma? What are the treatments for nasopharyngeal carcinoma?

The onset of nasopharyngeal carcinoma is to some extent related to the patient's age. So, what is the most common age for nasopharyngeal carcinoma? What are the treatments for nasopharyngeal carcinoma?

What is the most common age for nasopharyngeal cancer?

Nasopharyngeal carcinoma is one of the most common malignant tumors in my country. It is more common in southern provinces such as Guangdong, Guangxi, Hunan, Fujian, and Jiangxi. The incidence rate in men is 2 to 3 times that in women. The age distribution of reported cases in my country ranges from 3 to 90 years old, but 30 to 50 years old is the high-incidence age group.

What are the treatments for nasopharyngeal cancer?

1. Radiotherapy Radiotherapy is the first choice for the treatment of nasopharyngeal carcinoma. Cobalt-60 radiotherapy is superior to deep X-ray irradiation and can also be used in combination with intracavitary radium therapy. Radiotherapy has a more direct killing effect on cancer cells, but the adverse reactions are relatively large and will cause damage to normal cells.

2. Combined chemotherapy Chemotherapy can be used in conjunction with radiotherapy, or for palliative treatment of patients with advanced distant metastasis or recurrence after radiotherapy. Commonly used drugs include cisplatin, carboplatin, cyclophosphamide, bleomycin, 5-fluorouracil, etc. The effect is better than radiotherapy or chemotherapy alone.

3. Surgical treatment Due to the characteristics of nasopharyngeal carcinoma, surgery cannot be the first choice for treatment. However, surgery is still beneficial as a salvage treatment measure when recurrence occurs after radiotherapy.

4. Treatment with traditional Chinese medicine Traditional Chinese medicine plays an important role in the treatment of advanced nasopharyngeal carcinoma. It can not only reduce the toxic side effects of radiotherapy and chemotherapy on the human body, but also play a role in increasing efficacy and reducing toxicity in the treatment of advanced nasopharyngeal carcinoma.